Abstract

Palbociclib (PAL), in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy (ET) or with fulvestrant (FUL), is indicated for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) ABC/mBC. This analysis describes real-world patient (pt) characteristics, treatment patterns, and preliminary tumour response in pre/perimenopausal women with HR+/HER2– ABC/mBC enrolled in the POLARIS study.

Full Text

Published Version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract P2-16-33: Patient characteristics and real-world treatment patterns in patients with early-stage triple-negative breast cancer receiving neoadjuvant chemotherapy
Whitney C Rhodes ... Min Huang
Cancer Research | VOL. 80
Whitney C Rhodes, et. al.Whitney C Rhodes ... Min Huang
14 Feb 2020
Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia in China: A Retrospective Analysis Using a Real-World Database
Yin Liu ... Jifang Zhou
Blood | VOL. 142
Yin Liu, et. al.Yin Liu ... Jifang Zhou
28 Nov 2023
Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Mantle Cell Lymphoma in China: A Retrospective Analysis Using a Real-World Database
Yin Liu ... Yanfei Chen
Blood | VOL. 142
Yin Liu, et. al.Yin Liu ... Yanfei Chen
02 Nov 2023
Abstract P3-01-03: Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS
Debu Tripathy ... Gabrielle B Rocque
Cancer Research | VOL. 83
Debu Tripathy, et. al.Debu Tripathy ... Gabrielle B Rocque
01 Mar 2023
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study
T André ... L.A Diaz
Annals of Oncology | VOL. -
T André, et. al.T André ... L.A Diaz
01 Dec 2024
Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come
J.-Y Blay ... A Le Cesne
Annals of Oncology | VOL. 35
J.-Y Blay, et. al.J.-Y Blay ... A Le Cesne
01 Dec 2024
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”: [Ann Oncol 35 (2024) 1039-1047]
T.M Kim ... S Luminari
Annals of Oncology | VOL. -
T.M Kim, et. al.T.M Kim ... S Luminari
01 Dec 2024
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
A Di Federico ... J Luo
Annals of Oncology | VOL. -
A Di Federico, et. al.A Di Federico ... J Luo
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.